Lecture Notes

**Lecture Coverage:**
- Lipoprotein Metabolism and Dyslipidemia
- Statin
- Non-Statin Drugs

---
#### **Lipoprotein Metabolism and Dyslipidemia**
**Stages in Lipoprotein Metabolism**

|            Pathway            |       Location        | Event                                                                                                             |
| :---------------------------: | :-------------------: | ----------------------------------------------------------------------------------------------------------------- |
|         <br>Exogenous         |       Intestine       | Chylomicron absorb Dietary Fat (<abbr Title="Cholesteryl Ester">CE</abbr> & <abbr Title="Triglyceride">TG</abbr>) |
|               ^               |         Lymph         | Chylomicron loses TG by <abbr Title="Lipoprotein Lipase">LPL</abbr> → Chylomicron Remnant to Liver                |
|    <br><br><br>Endogenous     |         Liver         | VLDL Synthesis from CE & TG                                                                                       |
|               ^               | <br>Peripheral Tissue | VLDL loses FFA → IDL                                                                                              |
|               ^               |           ^           | IDL loses FFA → LDL                                                                                               |
|               ^               |           ^           | LDL release Chol to Peripheral Cells (Atherosclerosis)                                                            |
|               ^               |         Liver         | LDL returns to Liver                                                                                              |
| Reverse Cholesterol Transport |   Peripheral Tissue   | HDL takes up Chol in Peripheral Cells to Liver                                                                    |

**Roles of Apolipoprotein**

|  Apolipoprotein  | Role                                                                           |
| :--------------: | :----------------------------------------------------------------------------- |
|       A-I        | HDL Metabolism for Reverse Cholesterol Transport                               |
| (a), B-48, B-100 | Structural Backbone for Atherogenic Lipoprotein (Chylomicrons, VLDL, IDL, LDL) |
|  C-II, C-III, E  | Triglyceride-rich Lipoprotein Metabolism                                       |

**Dyslipidemia**
- Risk Factors for Cardiovascular Diseases
	- Causes: Genetic / Lifestyle (Obesity / Adiposopathy)
- Most Common Form: ↑ Plasma LDL-Cholesterol level
	- Diagnosed by ApoB level
	- Alleviated by ↑ HDL


#### **Statin**
- HMG-CoA Reductase Inhibitor
	- E.g. Atorvastatin

| Step | Event                        | Effect           |
| ---- | ---------------------------- | ---------------- |
| 1    | HMG-CoA Reductase Inhibition | ↓ Chol Synthesis |
| 2    | ↓ VLDL Synthesis             | ↓ Blood LDL & TG |

#### **Non-Statin Drugs**
**Fibrates (Fenofibrate)**
- Antilipemic Agent
	- ↑ Apo A-I Synthesis → ↑ HDL → ↑ Cholesterol Removal
	- ↑ TG Loss from Plasma LDL → ↓ TG Delivery to Liver → ↓ VLDL Synthesis

**Niacin (Nicotinic Acid / Vitamin B3)**
- ↓ Adipose Tissue FFA Release → ↓ TG Delivery to Liver → ↓ VLDL Synthesis
- Side Effects:
	- ↓ Insulin Sensitivity → Worsen Diabetes Mellitus
	- Facial Flushing & Dizziness
	- GI Discomfort, Diarrhea & Bloating

**Bile Acid Sequestrant (Cholestyramine)**
- Strongly +ve Charged Resin
	- Binds to -ve Bile Acid
- Blocks Bile Acid reabsorption in Intestines

**Cholesterol Absorption Inhibitor (Ezetimibe)**
- Intestinal NPC1L1 Inhibitor
	- ↓ Cholesterol Absorption & Reabsorption
- Used Alone / with Statin